Arcellx Q3 net loss narrows; anito-cel hits 95% ORR in pivotal study with no neurotoxicity

Arcellx, Inc.

2024-Q3 EPS reported -$1.13 revenue$92,670,000

Q3 net loss $25.9M ($39.3M YoY); collaboration revenue $26M from Kite expansion.
Phase 2 iMMagine-1 (n=58): 95% ORR, 62% CR/sCR, median follow-up 10.3 months; 92% MRD negativity.
Phase 1 anito-cel: 30.2-month mPFS, median OS not reached at 38.1 months; 100% ORR.
No delayed neurotoxicity (parkinsonism, cranial nerve palsies) in >140 patients across trials.
Cash $676.7M funds into 2027; first patients dosed in iMMagine-3 with Kite manufacturing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.